Literature DB >> 10886570

Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo.

S Nakamura1, I Nakamura, L Ma, D E Vaughan, A B Fogo.   

Abstract

BACKGROUND: The fibrinolytic system plays an important role in degrading fibrin-rich thrombi and in vascular and tissue remodeling. Elevated levels of plasminogen activator inhibitor-1 (PAI-1) can reduce the efficiency of the endogenous fibrinolytic system. Angiotensin (Ang) has been shown to regulate PAI-1 expression via the Ang type 1 (AT1) receptor in some tissues and via the AT4 receptor in cultured endothelium. The purpose of this study was to examine the tissue-specific pattern of PAI-1 expression in response to infusion of Ang II in vivo.
METHODS: Adult male Sprague-Dawley rats (N = 5 in each group) were treated with four hours of intravenous infusions of Ang II or vehicle control while mean arterial pressure (MAP) was monitored: group 1, 600 ng/kg/min Ang II; group 2, Ang II + 10 mg/kg of the AT1 receptor antagonist (AT1RA) L158-809 q2 hour; group 3, Ang II + 0.01 to 0.1 mg/kg hydralazine as required to maintain normal blood pressure; and group 4, saline-infused controls. After infusion, tissue was harvested for Northern blotting, immunohistochemical analysis, and in situ hybridization.
RESULTS: In group 1, Ang II infusion increased MAP from 105 +/- 8 to 160 +/- 9 mm Hg (mean +/- SE, P < 0. 01). Ang II induced increased expression of PAI-1 mRNA in all tissues examined from 5.1-fold in the heart, 9.7-fold in the kidney, 10.0-fold in the aorta, and up to 30.0-fold in the liver (all P < 0. 01 vs. control). While both AT1RA (group 3) and hydralazine (group 4) prevented Ang II-induced elevation in blood pressure, the Ang II-dependent expression of PAI-1 mRNA was reduced by only AT1 receptor blockade.
CONCLUSIONS: We conclude that in the rat, PAI-1 is induced in a variety of tissues by Ang II directly through the AT1 receptor, independent of its effects on blood pressure.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10886570     DOI: 10.1046/j.1523-1755.2000.00160.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  43 in total

1.  Overexpression of hepatic plasminogen activator inhibitor type 1 mRNA in rabbits with fatty liver.

Authors:  J G Fan; L H Chen; Z J Xu; M D Zeng
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

Review 2.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

3.  Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels.

Authors:  Folkert W Asselbergs; Scott M Williams; Patricia R Hebert; Christopher S Coffey; Hans L Hillege; Gerjan Navis; Douglas E Vaughan; Wiek H van Gilst; Jason H Moore
Journal:  Genomics       Date:  2007-01-05       Impact factor: 5.736

Review 4.  Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia.

Authors:  Yang Xia; Susan M Ramin; Rodney E Kellems
Journal:  Hypertension       Date:  2007-06-18       Impact factor: 10.190

Review 5.  Modulation of glomerulosclerosis.

Authors:  Li-Jun Ma; Agnes B Fogo
Journal:  Semin Immunopathol       Date:  2007-09-08       Impact factor: 9.623

6.  ACE gene insertion/deletion polymorphism in childhood idiopathic nephrotic syndrome.

Authors:  Erkin Serdaroglu; Sevgi Mir; Afig Berdeli; Nejat Aksu; Mustafa Bak
Journal:  Pediatr Nephrol       Date:  2005-10-06       Impact factor: 3.714

Review 7.  Angiotensin II and the glomerulus: focus on diabetic kidney disease.

Authors:  James W Scholey
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

Review 8.  Appropriate drug therapy for improving outcomes in diabetic nephropathy.

Authors:  Robert D Toto
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

Review 9.  Molecular mechanisms of angiotensin II-induced vascular injury.

Authors:  Marta Ruiz-Ortega; Monica Ruperez; Vanesa Esteban; Jesús Egido
Journal:  Curr Hypertens Rep       Date:  2003-02       Impact factor: 5.369

10.  The role of renin angiotensin system inhibition in kidney repair.

Authors:  Irene M van der Meer; Paolo Cravedi; Giuseppe Remuzzi
Journal:  Fibrogenesis Tissue Repair       Date:  2010-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.